# **OPTIMIZATION OF ADHESIVE, 3D-PRINTED HYDROGEL PATCHES AS A DRUG DELIVERY SYSTEM FOR WOUND HEALING**

Srilekha Venkatraman<sup>1</sup>, Emma Etter<sup>1</sup>, Juliane Nguyen<sup>2</sup> <sup>1</sup>Joint Department of Biomedical Engineering at UNC Chapel Hill and NC State; <sup>2</sup>UNC Eshelman School of Pharmacy Division of Pharmacoengineering and Molecular Pharmaceutics

#### BACKGROUND

#### **INTRODUCTION:**

- >2.5 million people affected by chronic wounds in the US annually
- Current growth factor treatments
- targetting complications in angiogenesis have low bioavailability

**PROPOSAL:** Protein-delivering, adhesive, hydrogel patches (PAdH) patches for the delivery of therapeutic protein (PDGF) to facilitate wound healing

**PURPOSE:** Optimize PAdH patch composition for delivery of therapeutic proteins

#### **OBJECTIVES:**

Protein loading and release efficiency

- Maximize amount of protein loaded into crosslinked ink
- Sustain the release of protein from the patch
- Ensure appropriate rate of release of PDGF for accurate dosing of therapeutic
- Degradation of PAdH patches in collagenase • Fabricate patches for resistance to degradation in physiological levels of
  - collagenase • Gelatin is derived from collagenase,
  - which is broken down by collagen
- Establish longevity of patch for use in long-term wound treatment

### METHODS

#### PATCH COMPOSITION AND **PRINTING:**

- Gelatin methacrylate-based (GelMA)
- Square patch; photocrosslinked with UV light in 3D printer


#### **PROTEIN RELEASE:**

- Ink loaded with PDGF
- Patch put in PBS solution
- PBS solution obtained and changed over a series of days
- ELISA conducted on supernatants
- **PROTEIN LOADING:**
- Print patches loaded with green fluorescent protein (GFP)
- Patches homogenized and analyzed with ELISA

#### **PATCH DEGRADATION:**

- Patches put in collagenase solutions
- Patch weights and areas recorded over a series of days

## **RESULTS - PROTEIN LOADING AND RELEASE**



There is sustained release of PDGF from patches over time for 3 days.


Patch

.⊑

GFр

%


**Bioink under light** 



Remaining GFP in crosslinked ink




# PAdH patches are resistant to degradation and exhibit sustained release of wound healing proteins.



# **RESULTS - PATCH DEGRADATION**





PAdH patches undergo less degradation in physiological levels of collagenase

Percent GFP Loaded 100-79.1% 78.5% 76.9% 80-60 40 20


100 ng

The concentration of GFP loaded into the ink does not affect the amount present in the patch

GFP Loaded

250 ng 500 ng

% GFP Loaded = amount in uncrosslinked ink, 100 - 100 ( total GFP loaded



Physiological levels of collagenase facilitate patch swelling and resistance to degradation.

# CONCLUSION

#### **DISCUSSION:**

- efficiency
- patches for 3 days







#### **DEGRADATION BASED ON WEIGHT**

# % Weight Change

Collagenase Conc. 1 ug/mL 500 ug/mL -1000 ug/mL



# **TOTAL WEIGHT DEGRADATION**



PAdH patches in physiological levels of collagenase swell similarly to patches in water.

## **DEGRADATION BASED ON AREA**

## % Area Change Collagenase Conc. **→** 0 🗕 1 ug/mL 🛨 500 ug/mL 🕂 1000 ug/mL 1ug/mL 500 ug/mL 20 25 Time (Days) Collagenase Changes . . . . . 1000 ug/mL

in no collagenase.

 PAdH patches are resistant to degradation in physiological levels of collagenase for 25 days • GFP successfully loaded into PAdH patches at 78%


• Observed sustained release of PDGF from PAdH

#### **FUTURE DIRECTIONS:**

- Further optimize protein release
- Load yeast into patches

  - Observe patch degradation with loaded yeast

# **ESHELMAN SCHOOL OF PHARMACY**




**TOTAL AREA DEGRADATION** 

% Area @ 25 days

800<sub>7</sub> % 600-383.0% Initia 171.4% 500 1000 Collagenase Conc. (µg/mL)

PAdH patches are more resistant to area decrease in physiological levels of collagenase

#### **IMAGES OF PATCH DEGRADATION**



# Patch Images

PAdH patches in physiological levels of collagenase exhibit similar swelling to patches

• Investigate potential for controlled release of PDGF • Introduce engineered yeast (*S. cerevisiae*) as a drug delivery agent to secrete PDGF

• Test loading and release efficiency of PDGF with yeast delivery

FUNDING:



National Institute of

Created with BioRender Poster Builde